$AISF Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PLURISTEM THERAPEUTICS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PLURISTEM THERAPEUTICS INC. Get notifications about new insider transactions in PLURISTEM THERAPEUTICS INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.72 | 45,000 | 167,400 | 3,121,918 | 3.2 M to 3.1 M (-1.42 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.72 | 45,000 | 167,400 | 3,121,918 | 3.2 M to 3.1 M (-1.42 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.72 | 70,007 | 260,426 | 3,166,918 | 3.2 M to 3.2 M (-2.16 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.72 | 70,007 | 260,426 | 3,166,918 | 3.2 M to 3.2 M (-2.16 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.69 | 24,110 | 88,966 | 3,236,925 | 3.3 M to 3.2 M (-0.74 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.69 | 24,110 | 88,966 | 3,236,925 | 3.3 M to 3.2 M (-0.74 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.69 | 71,775 | 264,850 | 3,261,035 | 3.3 M to 3.3 M (-2.15 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.69 | 71,775 | 264,850 | 3,261,035 | 3.3 M to 3.3 M (-2.15 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.69 | 22,015 | 81,235 | 3,332,810 | 3.4 M to 3.3 M (-0.66 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.69 | 22,015 | 81,235 | 3,332,810 | 3.4 M to 3.3 M (-0.66 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.68 | 122,663 | 451,400 | 3,354,825 | 3.5 M to 3.4 M (-3.53 %) |
Jun 01 2021 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Sell | S | 3.68 | 122,663 | 451,400 | 3,354,825 | 3.5 M to 3.4 M (-3.53 %) |
Jan 07 2021 | AISF | PLURISTEM THERAPEU ... | Levi Rami Avraham | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
Dec 01 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.70 | 20,000 | 194,000 | 4,077,589 | 4.1 M to 4.1 M (+0.49 %) |
Nov 03 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.42 | 25,000 | 235,500 | 4,057,589 | 4 M to 4.1 M (+0.62 %) |
Nov 03 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.60 | 25,000 | 240,000 | 4,032,589 | 4 M to 4 M (+0.62 %) |
Nov 03 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.42 | 25,000 | 235,500 | 4,057,589 | 4 M to 4.1 M (+0.62 %) |
Nov 03 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.60 | 25,000 | 240,000 | 4,032,589 | 4 M to 4 M (+0.62 %) |
Oct 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.20 | 20,000 | 184,000 | 4,007,589 | 4 M to 4 M (+0.50 %) |
Oct 01 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 10.34 | 139,006 | 1,437,322 | 3,987,589 | 3.8 M to 4 M (+3.61 %) |
Oct 01 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.76 | 60,123 | 586,800 | 3,848,583 | 3.8 M to 3.8 M (+1.59 %) |
Sep 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.49 | 13,189 | 125,164 | 3,788,460 | 3.8 M to 3.8 M (+0.35 %) |
Sep 25 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.02 | 34,800 | 313,896 | 3,775,271 | 3.7 M to 3.8 M (+0.93 %) |
Sep 24 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 8.98 | 2,276 | 20,438 | 3,740,471 | 3.7 M to 3.7 M (+0.06 %) |
Sep 24 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.05 | 8,458 | 76,545 | 3,738,195 | 3.7 M to 3.7 M (+0.23 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Grant | A | 0.00 | 20,000 | 0 | 57,357 | 37.4 K to 57.4 K (+53.54 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Grant | A | 0.00 | 20,000 | 0 | 82,569 | 62.6 K to 82.6 K (+31.96 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Grant | A | 0.00 | 20,000 | 0 | 66,474 | 46.5 K to 66.5 K (+43.03 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Grant | A | 0.00 | 20,000 | 0 | 83,621 | 63.6 K to 83.6 K (+31.44 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | Franco-Yehuda Chen | Chief Financial Off ... | Grant | A | 0.00 | 100,000 | 0 | 117,716 | 17.7 K to 117.7 K (+564.46 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CEO & President | Grant | A | 0.00 | 500,000 | 0 | 1,425,304 | 925.3 K to 1.4 M (+54.04 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CEO & President | Grant | A | 0.00 | 500,000 | 0 | 925,304 | 425.3 K to 925.3 K (+117.56 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | Executive Chairman | Grant | A | 0.00 | 500,000 | 0 | 1,493,973 | 994 K to 1.5 M (+50.30 %) |
Sep 10 2020 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | Executive Chairman | Grant | A | 0.00 | 500,000 | 0 | 993,973 | 494 K to 994 K (+101.22 %) |
Aug 03 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.43 | 14,536 | 137,074 | 3,729,737 | 3.7 M to 3.7 M (+0.39 %) |
Aug 03 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.19 | 51,235 | 470,850 | 3,715,201 | 3.7 M to 3.7 M (+1.40 %) |
Jul 30 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 9.03 | 121,926 | 1,100,992 | 3,663,966 | 3.5 M to 3.7 M (+3.44 %) |
Jul 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 8.46 | 81,198 | 686,935 | 3,542,040 | 3.5 M to 3.5 M (+2.35 %) |
Jul 28 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 8.34 | 49,396 | 411,963 | 3,460,842 | 3.4 M to 3.5 M (+1.45 %) |
Jul 07 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 8.41 | 110,897 | 932,644 | 3,411,446 | 3.3 M to 3.4 M (+3.36 %) |
Jul 07 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 8.05 | 25,000 | 201,250 | 3,300,549 | 3.3 M to 3.3 M (+0.76 %) |
Jul 07 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.67 | 4,789 | 36,732 | 3,275,549 | 3.3 M to 3.3 M (+0.15 %) |
Jul 07 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.36 | 59,000 | 434,240 | 3,270,760 | 3.2 M to 3.3 M (+1.84 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.36 | 49,000 | 360,640 | 3,211,760 | 3.2 M to 3.2 M (+1.55 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 6.91 | 25,000 | 172,750 | 3,162,760 | 3.1 M to 3.2 M (+0.80 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.15 | 72,142 | 515,815 | 3,137,760 | 3.1 M to 3.1 M (+2.35 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.36 | 178,717 | 1,315,357 | 3,065,618 | 2.9 M to 3.1 M (+6.19 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.82 | 60,000 | 469,200 | 2,886,901 | 2.8 M to 2.9 M (+2.12 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.86 | 7,610 | 59,815 | 2,826,901 | 2.8 M to 2.8 M (+0.27 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.57 | 117,489 | 889,392 | 2,819,291 | 2.7 M to 2.8 M (+4.35 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.85 | 22,796 | 178,949 | 2,701,802 | 2.7 M to 2.7 M (+0.85 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 7.95 | 1,797 | 14,286 | 2,679,006 | 2.7 M to 2.7 M (+0.07 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 8.16 | 75,898 | 619,328 | 2,677,209 | 2.6 M to 2.7 M (+2.92 %) |
Jun 29 2020 | AISF | PLURISTEM THERAPEU ... | CLOVER WOLF CAPITAL - LIMITED ... | 10% Owner | Buy | P | 8.14 | 90,000 | 732,600 | 2,601,311 | 2.5 M to 2.6 M (+3.58 %) |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Option Exercise | P | 0.70 | 14,286 | 10,000 | 14,286 | |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Buy | P | 0.70 | 14,286 | 10,000 | 464,744 | 450.5 K to 464.7 K (+3.17 %) |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | Co-CEO & Chairman | Option Exercise | P | 0.70 | 71,429 | 50,000 | 71,429 | |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | Co-CEO & Chairman | Buy | P | 0.70 | 71,429 | 50,000 | 4,939,727 | 4.9 M to 4.9 M (+1.47 %) |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | Co-CEO & President | Option Exercise | P | 0.70 | 71,429 | 50,000 | 71,429 | |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | Co-CEO & President | Buy | P | 0.70 | 71,429 | 50,000 | 4,253,045 | 4.2 M to 4.3 M (+1.71 %) |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Option Exercise | P | 0.70 | 71,429 | 50,000 | 71,429 | |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 0.70 | 71,429 | 50,000 | 387,235 | 315.8 K to 387.2 K (+22.62 %) |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Option Exercise | P | 0.70 | 28,571 | 20,000 | 28,571 | |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Buy | P | 0.70 | 28,571 | 20,000 | 373,571 | 345 K to 373.6 K (+8.28 %) |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Option Exercise | P | 0.70 | 50,000 | 35,000 | 50,000 | |
Apr 08 2019 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Buy | P | 0.70 | 50,000 | 35,000 | 636,208 | 586.2 K to 636.2 K (+8.53 %) |
Mar 28 2019 | AISF | PLURISTEM THERAPEU ... | Franco-Yehuda Chen | Chief Financial Off ... | Grant | A | 0.00 | 40,000 | 0 | 177,158 | 137.2 K to 177.2 K (+29.16 %) |
Mar 28 2019 | AISF | PLURISTEM THERAPEU ... | Franco-Yehuda Chen | Chief Financial Off ... | Grant | A | 0.00 | 60,000 | 0 | 137,158 | 77.2 K to 137.2 K (+77.76 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | Co-CEO & Chairman | Grant | A | 0.00 | 250,000 | 0 | 4,868,298 | 4.6 M to 4.9 M (+5.41 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | Co-CEO & Chairman | Grant | A | 0.00 | 300,000 | 0 | 4,618,298 | 4.3 M to 4.6 M (+6.95 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | Co-CEO & President | Grant | A | 0.00 | 250,000 | 0 | 4,181,616 | 3.9 M to 4.2 M (+6.36 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | Co-CEO & President | Grant | A | 0.00 | 280,000 | 0 | 3,931,616 | 3.7 M to 3.9 M (+7.67 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | ROSMAN NACHUM | Director | Grant | A | 0.00 | 49,875 | 0 | 633,714 | 583.8 K to 633.7 K (+8.54 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | ROSMAN NACHUM | Director | Grant | A | 0.00 | 63,375 | 0 | 583,839 | 520.5 K to 583.8 K (+12.18 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Grant | A | 0.00 | 33,750 | 0 | 345,000 | 311.3 K to 345 K (+10.84 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Grant | A | 0.00 | 33,750 | 0 | 311,250 | 277.5 K to 311.3 K (+12.16 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Grant | A | 0.00 | 49,125 | 0 | 625,694 | 576.6 K to 625.7 K (+8.52 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Grant | A | 0.00 | 62,625 | 0 | 576,569 | 513.9 K to 576.6 K (+12.19 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Grant | A | 0.00 | 33,750 | 0 | 586,208 | 552.5 K to 586.2 K (+6.11 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Grant | A | 0.00 | 47,250 | 0 | 552,458 | 505.2 K to 552.5 K (+9.35 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Grant | A | 0.00 | 49,875 | 0 | 315,806 | 265.9 K to 315.8 K (+18.75 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Grant | A | 0.00 | 49,875 | 0 | 265,931 | 216.1 K to 265.9 K (+23.08 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | MERETZKI HAVA | Director | Grant | A | 0.00 | 33,750 | 0 | 586,208 | 552.5 K to 586.2 K (+6.11 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | MERETZKI HAVA | Director | Grant | A | 0.00 | 47,250 | 0 | 552,458 | 505.2 K to 552.5 K (+9.35 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | Egozi Erez | Chief Financial Off ... | Grant | A | 0.00 | 30,000 | 0 | 548,000 | 518 K to 548 K (+5.79 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | Egozi Erez | Chief Financial Off ... | Grant | A | 0.00 | 50,000 | 0 | 518,000 | 468 K to 518 K (+10.68 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | Egozi Erez | Chief Financial Off ... | Grant | A | 0.00 | 80,000 | 0 | 468,000 | 388 K to 468 K (+20.62 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Grant | A | 0.00 | 49,875 | 0 | 450,458 | 400.6 K to 450.5 K (+12.45 %) |
Dec 20 2018 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Grant | A | 0.00 | 63,375 | 0 | 400,583 | 337.2 K to 400.6 K (+18.79 %) |
Mar 19 2018 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Sell | S | 1.48 | 11,640 | 17,227 | 513,944 | 525.6 K to 513.9 K (-2.21 %) |
Mar 19 2018 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Sell | S | 1.48 | 34,233 | 50,665 | 525,584 | 559.8 K to 525.6 K (-6.12 %) |
Mar 15 2018 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Sell | S | 1.50 | 23,818 | 35,727 | 559,817 | 583.6 K to 559.8 K (-4.08 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Grant | A | 0.00 | 90,000 | 0 | 505,208 | 415.2 K to 505.2 K (+21.68 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | MERETZKI HAVA | Director | Grant | A | 0.00 | 90,000 | 0 | 505,208 | 415.2 K to 505.2 K (+21.68 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Grant | A | 0.00 | 133,000 | 0 | 411,250 | 278.3 K to 411.3 K (+47.80 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Grant | A | 0.00 | 133,000 | 0 | 769,708 | 636.7 K to 769.7 K (+20.89 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Grant | A | 0.00 | 131,000 | 0 | 583,635 | 452.6 K to 583.6 K (+28.94 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | Egozi Erez | Chief Financial Off ... | Grant | A | 0.00 | 110,000 | 0 | 388,000 | 278 K to 388 K (+39.57 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | ROSMAN NACHUM | Director | Grant | A | 0.00 | 133,000 | 0 | 520,464 | 387.5 K to 520.5 K (+34.33 %) |
Dec 14 2017 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Grant | A | 0.00 | 90,000 | 0 | 277,500 | 187.5 K to 277.5 K (+48.00 %) |
Jun 23 2017 | AISF | PLURISTEM THERAPEU ... | Egozi Erez | Chief Financial Off ... | Grant | A | 0.00 | 150,000 | 0 | 278,000 | 128 K to 278 K (+117.19 %) |
Jun 23 2017 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | Co-CEO & President | Grant | A | 0.00 | 2,000,000 | 0 | 3,651,616 | 1.7 M to 3.7 M (+121.09 %) |
Jun 23 2017 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | Co-CEO & Chairman | Grant | A | 0.00 | 2,000,000 | 0 | 4,318,298 | 2.3 M to 4.3 M (+86.27 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Grant | A | 0.00 | 200,000 | 0 | 2,318,298 | 2.1 M to 2.3 M (+9.44 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Grant | A | 0.00 | 200,000 | 0 | 1,651,616 | 1.5 M to 1.7 M (+13.78 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | ROSMAN NACHUM | Director | Grant | A | 0.00 | 66,500 | 0 | 387,464 | 321 K to 387.5 K (+20.72 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Grant | A | 0.00 | 45,000 | 0 | 187,500 | 142.5 K to 187.5 K (+31.58 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Grant | A | 0.00 | 65,500 | 0 | 452,635 | 387.1 K to 452.6 K (+16.92 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Grant | A | 0.00 | 45,000 | 0 | 415,208 | 370.2 K to 415.2 K (+12.16 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Grant | A | 0.00 | 66,500 | 0 | 278,250 | 211.8 K to 278.3 K (+31.40 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | MERETZKI HAVA | Director | Grant | A | 0.00 | 45,000 | 0 | 415,208 | 370.2 K to 415.2 K (+12.16 %) |
Dec 29 2016 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Grant | A | 0.00 | 66,500 | 0 | 636,708 | 570.2 K to 636.7 K (+11.66 %) |
Jun 06 2016 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Sell | S | 1.52 | 12,346 | 18,784 | 570,208 | 582.6 K to 570.2 K (-2.12 %) |
Feb 24 2016 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 1.33 | 5,000 | 6,650 | 111,400 | 106.4 K to 111.4 K (+4.70 %) |
Feb 22 2016 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Buy | P | 1.20 | 5,000 | 6,000 | 66,499 | 61.5 K to 66.5 K (+8.13 %) |
Feb 17 2016 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 1.06 | 6,000 | 6,360 | 106,400 | 100.4 K to 106.4 K (+5.98 %) |
Feb 17 2016 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 1.07 | 9,000 | 9,630 | 100,400 | 91.4 K to 100.4 K (+9.85 %) |
Feb 17 2016 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Buy | P | 1.07 | 7,500 | 8,025 | 61,499 | 54 K to 61.5 K (+13.89 %) |
Feb 17 2016 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Buy | P | 0.83 | 7,500 | 6,225 | 53,999 | 46.5 K to 54 K (+16.13 %) |
Feb 17 2016 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Buy | P | 0.81 | 12,346 | 9,968 | 582,554 | 570.2 K to 582.6 K (+2.17 %) |
Feb 16 2016 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 0.79 | 10,000 | 7,900 | 216,056 | 206.1 K to 216.1 K (+4.85 %) |
Feb 16 2016 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Buy | P | 0.83 | 5,000 | 4,139 | 46,499 | 41.5 K to 46.5 K (+12.05 %) |
Feb 16 2016 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 0.80 | 31,000 | 24,716 | 91,400 | 60.4 K to 91.4 K (+51.32 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Grant | A | 0.00 | 49,000 | 0 | 211,750 | 162.8 K to 211.8 K (+30.11 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Grant | A | 0.00 | 150,000 | 0 | 2,118,298 | 2 M to 2.1 M (+7.62 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Grant | A | 0.00 | 150,000 | 0 | 1,451,616 | 1.3 M to 1.5 M (+11.52 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | ROSMAN NACHUM | Director | Grant | A | 0.00 | 49,000 | 0 | 320,964 | 272 K to 321 K (+18.02 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | Kwiat Moria | Director | Grant | A | 0.00 | 35,000 | 0 | 142,500 | 107.5 K to 142.5 K (+32.56 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | GERMAIN MARK | Director | Grant | A | 0.00 | 48,000 | 0 | 387,135 | 339.1 K to 387.1 K (+14.15 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | BRAUN ISAAC | Director | Grant | A | 0.00 | 35,000 | 0 | 370,208 | 335.2 K to 370.2 K (+10.44 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | MERETZKI HAVA | Director | Grant | A | 0.00 | 35,000 | 0 | 370,208 | 335.2 K to 370.2 K (+10.44 %) |
Jan 07 2016 | AISF | PLURISTEM THERAPEU ... | SHORRER DORON | Director | Grant | A | 0.00 | 49,000 | 0 | 570,208 | 521.2 K to 570.2 K (+9.40 %) |
Nov 17 2015 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 1.49 | 9,900 | 14,751 | 60,400 | 50.5 K to 60.4 K (+19.60 %) |
Nov 17 2015 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Buy | P | 1.52 | 10,000 | 15,200 | 41,499 | 31.5 K to 41.5 K (+31.75 %) |
Sep 24 2015 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 2.14 | 3,300 | 7,062 | 206,056 | 202.8 K to 206.1 K (+1.63 %) |
Sep 24 2015 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 2.11 | 3,900 | 8,229 | 202,756 | 198.9 K to 202.8 K (+1.96 %) |
Sep 24 2015 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 2.10 | 7,200 | 15,120 | 198,856 | 191.7 K to 198.9 K (+3.76 %) |
Sep 24 2015 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 2.09 | 100 | 209 | 191,656 | 191.6 K to 191.7 K (+0.05 %) |
Sep 24 2015 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 2.08 | 3,200 | 6,656 | 191,556 | 188.4 K to 191.6 K (+1.70 %) |
Sep 24 2015 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Buy | P | 2.07 | 12,300 | 25,461 | 188,356 | 176.1 K to 188.4 K (+6.99 %) |
Sep 24 2015 | AISF | PLURISTEM THERAPEU ... | BEN-YORAM ISRAEL | Director | Sell | S | 2.10 | 30,000 | 63,000 | 176,056 | 206.1 K to 176.1 K (-14.56 %) |
Sep 21 2015 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | CFO, COO & Presiden ... | Buy | P | 2.11 | 10,000 | 21,100 | 31,499 | 21.5 K to 31.5 K (+46.51 %) |
Sep 21 2015 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 2.10 | 14,000 | 29,400 | 50,500 | 36.5 K to 50.5 K (+38.36 %) |
Sep 21 2015 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 2.12 | 11,500 | 24,380 | 36,500 | 25 K to 36.5 K (+46.00 %) |
Sep 17 2015 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | COO, CFO & Presiden ... | Buy | P | 2.14 | 4,500 | 9,630 | 21,499 | 17 K to 21.5 K (+26.47 %) |
Sep 17 2015 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | COO, CFO & Presiden ... | Buy | P | 2.10 | 2,000 | 4,200 | 16,999 | 15 K to 17 K (+13.33 %) |
Sep 17 2015 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | COO, CFO & Presiden ... | Buy | P | 2.12 | 500 | 1,060 | 14,999 | 14.5 K to 15 K (+3.45 %) |
Sep 17 2015 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | COO, CFO & Presiden ... | Buy | P | 2.09 | 2,500 | 5,225 | 14,499 | 12 K to 14.5 K (+20.84 %) |
Sep 17 2015 | AISF | PLURISTEM THERAPEU ... | YANAY YAKY | COO, CFO & Presiden ... | Buy | P | 2.08 | 500 | 1,040 | 11,999 | 11.5 K to 12 K (+4.35 %) |
Sep 16 2015 | AISF | PLURISTEM THERAPEU ... | Aberman Zami | CEO & Chairman | Buy | P | 2.15 | 5,000 | 10,750 | 25,000 | 20 K to 25 K (+25.00 %) |